Lew Cantley (Cornell)
November 11, 2021 10:07 AM ESTUpdated 11:00 AM
R&D

Scoop: Famed can­cer re­searcher — and biotech founder — Lew Cant­ley is head­ed to Dana-Far­ber

John Carroll

Editor & Founder

Lew Cant­ley, the famed can­cer re­searcher best known for his dis­cov­ery of the PI3K path­way and his ground­break­ing work on can­cer me­tab­o­lism, is head­ed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

As­traZeneca’s SERD hits pri­ma­ry end­point in late-stage tri­al, but first-line po­ten­tial re­mains un­cer­tain

Up­dat­ed: Lil­ly joins Trump ad­min­is­tra­tion to an­nounce $27B man­u­fac­tur­ing com­mit­ment

Eikon Ther­a­peu­tics rais­es $351M Se­ries D as lead drug starts Phase 3

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Re­gen­eron, two Chi­nese biotechs tout promise of their hear­ing loss gene ther­a­pies

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times